Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Elevation Oncology, Inc. (ELEV : NSDQ)

• Company Description    Elevation Oncology Inc. is a clinical stage biopharmaceutical company. It focused on the development of precision medicines for patients with genomically defined cancers. Elevation Oncology Inc. is based in NEW YORK. Number of Employees: 35

• Price / Volume Information    Yesterday's Closing Price: $3.64 Daily Weekly Monthly 20 Day Moving Average: 45,120 shares Shares Outstanding: 23.25 (millions) Market Capitalization: $84.64 (millions) Beta: 52 Week High: $16.22 52 Week Low: $2.28 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 54.89% 69.72% 12 Week 2.25% 10.94% Year To Date -39.53% -28.10%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 888 Seventh Ave.12th Floor - New York,NY 10106 USA ph: 716-371-1125 fax: - ir@elevationoncology.com https://elevationoncology.com

• General Corporate Information    Officers Shawn Leland - President; Chief Executive Officer and Director Steven A. Elms - Chairman Joseph J. Ferra - Chief Financial Officer and Corporate Secretary R. Michael Carruthers - Director Timothy Clackson - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28623U101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 23.25 Most Recent Split Date: (:1) Beta: Market Capitalization: $84.64 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.80 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.84 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.68 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -80.49% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -31.06 12/31/21 - -28.76 09/30/21 - - ROA 03/31/22 - -29.41 12/31/21 - -27.44 09/30/21 - - Current Ratio 03/31/22 - 12.86 12/31/21 - 17.00 09/30/21 - 17.84 Quick Ratio 03/31/22 - 12.87 12/31/21 - 17.00 09/30/21 - 17.84 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 5.33 12/31/21 - 6.06 09/30/21 - 6.44 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©